DOP2012000232A - Proteínas de unión a antigeno especificas para el componente amiloide serico p - Google Patents

Proteínas de unión a antigeno especificas para el componente amiloide serico p

Info

Publication number
DOP2012000232A
DOP2012000232A DO2012000232A DO2012000232A DOP2012000232A DO P2012000232 A DOP2012000232 A DO P2012000232A DO 2012000232 A DO2012000232 A DO 2012000232A DO 2012000232 A DO2012000232 A DO 2012000232A DO P2012000232 A DOP2012000232 A DO P2012000232A
Authority
DO
Dominican Republic
Prior art keywords
amiloid
component
antigen binding
binding proteins
serico
Prior art date
Application number
DO2012000232A
Other languages
English (en)
Inventor
Volker Germaschewski
Tejinder Kaur Bhinder
Susannah Karen Ford
Alan Peter Lewis
Mark Brian Pepys
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2012000232A publication Critical patent/DOP2012000232A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A PROTEÍNAS DE UNIÓN A ANTÍGENO, TALES COMO ANTICUERPOS, QUE SE UNEN AL COMPONENTE AMILOIDE SÉRICO P (SAP), A POLINUCLEÓTIDOS QUE CODIFICAN DICHAS PROTEÍNAS DE UNIÓN A ANTÍGENO, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHAS PROTEÍNAS DE UNIÓN A ANTÍGENO Y A PROCEDIMIENTOS DE FABRICACIÓN. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE AL USO DE DICHAS PROTEÍNAS DE UNIÓN A ANTÍGENO EN EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON DEPOSICIÓN AMILOIDE QUE INCLUYEN AMILOIDOSIS SISTÉMICA, AMILOIDOSIS LOCAL, ENFERMEDAD DE ALZHEIMER Y DIABETES DE TIPO 2.
DO2012000232A 2010-03-03 2012-08-22 Proteínas de unión a antigeno especificas para el componente amiloide serico p DOP2012000232A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
DOP2012000232A true DOP2012000232A (es) 2013-01-15

Family

ID=43881068

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000232A DOP2012000232A (es) 2010-03-03 2012-08-22 Proteínas de unión a antigeno especificas para el componente amiloide serico p

Country Status (39)

Country Link
EP (2) EP3025729B1 (es)
JP (2) JP5922592B2 (es)
KR (1) KR101817265B1 (es)
CN (1) CN102858371B (es)
AR (1) AR080432A1 (es)
AU (1) AU2011223048C1 (es)
BR (1) BR112012021926A2 (es)
CA (1) CA2789557A1 (es)
CL (1) CL2012002418A1 (es)
CO (1) CO6602134A2 (es)
CR (1) CR20120491A (es)
CY (2) CY1118046T1 (es)
DK (2) DK3025729T3 (es)
DO (1) DOP2012000232A (es)
EA (1) EA026375B1 (es)
ES (2) ES2699078T3 (es)
HK (2) HK1173959A1 (es)
HR (2) HRP20161096T1 (es)
HU (1) HUE028960T2 (es)
IL (2) IL221418A (es)
JO (1) JO3188B1 (es)
LT (2) LT3025729T (es)
MA (1) MA34135B1 (es)
ME (1) ME02491B (es)
MX (1) MX340350B (es)
MY (1) MY159255A (es)
NZ (1) NZ601763A (es)
PE (1) PE20130040A1 (es)
PL (2) PL3025729T3 (es)
PT (2) PT3025729T (es)
RS (2) RS57708B1 (es)
SG (2) SG10201500382SA (es)
SI (2) SI3025729T1 (es)
SM (1) SMT201600337B (es)
TW (1) TWI558409B (es)
UA (1) UA108227C2 (es)
UY (1) UY33258A (es)
WO (1) WO2011107480A1 (es)
ZA (1) ZA201206529B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2673908C2 (ru) 2009-12-02 2018-12-03 Имэджинэб, Инк. Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
JP6449777B2 (ja) * 2012-12-21 2019-01-09 シアトル ジェネティックス， インコーポレイテッド 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
CA2994951A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
ES2182203T3 (es) 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
KR100960560B1 (ko) 2002-09-27 2010-06-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
EP1576368B1 (en) 2002-12-23 2009-02-18 William Marsh Rice Univeristy Methods and compositions for enhancing fibrocyte formation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2525302A1 (en) 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component
EP1776385A1 (en) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
GB0712503D0 (en) * 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use

Also Published As

Publication number Publication date
IL251031A0 (en) 2017-04-30
AU2011223048B2 (en) 2013-12-19
JP2016154535A (ja) 2016-09-01
PT2542261T (pt) 2016-09-27
PL3025729T3 (pl) 2019-02-28
AR080432A1 (es) 2012-04-11
ZA201206529B (en) 2018-12-19
MX340350B (es) 2016-07-06
RS55133B1 (sr) 2016-12-30
AU2011223048A1 (en) 2012-10-04
CA2789557A1 (en) 2011-09-09
CN102858371A (zh) 2013-01-02
SG183316A1 (en) 2012-09-27
CR20120491A (es) 2013-02-20
JP5922592B2 (ja) 2016-05-24
BR112012021926A2 (pt) 2020-08-25
EP2542261A1 (en) 2013-01-09
TW201143789A (en) 2011-12-16
JP6236478B2 (ja) 2017-11-22
HUE028960T2 (en) 2017-01-30
KR101817265B1 (ko) 2018-01-10
SI2542261T1 (sl) 2016-11-30
EA026375B1 (ru) 2017-04-28
IL221418A0 (en) 2012-10-31
AU2011223048C1 (en) 2018-06-21
RS57708B1 (sr) 2018-12-31
JP2013521252A (ja) 2013-06-10
ME02491B (me) 2017-02-20
SMT201600337B (it) 2016-11-10
IL221418A (en) 2017-03-30
CY1118046T1 (el) 2017-05-17
LT2542261T (lt) 2016-09-26
JO3188B1 (ar) 2018-03-08
CL2012002418A1 (es) 2013-03-08
CO6602134A2 (es) 2013-01-18
HRP20161096T1 (hr) 2016-11-04
MX2012010129A (es) 2012-09-12
HRP20181666T1 (hr) 2018-12-14
SG10201500382SA (en) 2015-03-30
EP3025729A1 (en) 2016-06-01
PE20130040A1 (es) 2013-02-09
ES2593454T3 (es) 2016-12-09
NZ601763A (en) 2014-08-29
WO2011107480A1 (en) 2011-09-09
HK1223292A1 (zh) 2017-07-28
EA201290671A1 (ru) 2013-05-30
IL251031A (en) 2017-11-30
UA108227C2 (xx) 2015-04-10
LT3025729T (lt) 2018-12-10
KR20130027483A (ko) 2013-03-15
ES2699078T3 (es) 2019-02-07
CY1120803T1 (el) 2019-12-11
TWI558409B (zh) 2016-11-21
DK3025729T3 (en) 2018-11-26
SI3025729T1 (sl) 2018-11-30
PT3025729T (pt) 2018-11-30
MY159255A (en) 2016-12-30
HK1173959A1 (zh) 2013-05-31
DK2542261T3 (en) 2016-09-19
CN102858371B (zh) 2017-03-01
EP2542261B1 (en) 2016-07-06
PL2542261T3 (pl) 2016-12-30
MA34135B1 (fr) 2013-04-03
EP3025729B1 (en) 2018-09-12
UY33258A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
DOP2021000005A (es) Proteínas de unión a pd1 y/o lag3
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
AU2018256498A1 (en) Antibodies to amyloid beta
CL2019000643A1 (es) Anticuerpos de unión a cd3.
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
AR092818A1 (es) Anticuerpo tau humanizado
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
EA201790757A1 (ru) Связывающие антиген cd27l белки
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201400579A1 (ru) Антитела к il-36r
UY32341A (es) Proteínas de unión antígeno novedosas
UY33274A (es) Proteínas de unión a basigina
EA201500503A1 (ru) Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana
AR124605A2 (es) Anticuerpos anti-il-36r